Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +55.52%
#3 Glidr Glidr +38.71%
#4 Cysic Cysic +28.33%
#5 Walrus Walrus +25.77%
#6 Humanity Humanity +25.08%
#7 Enso Enso +18.12%
#8 Velvet Velvet +16.00%
#9 Tutorial Tutorial +15.35%
#10 OVERTAKE OVERTAKE +15.31%
Coin of the day
EXOD EXOD
Instellingen
Taal
DUTCH
Valuta
USD
Thema
Quantum Genomics S.A. Quantum Genomics S.A.

Quantum Genomics S.A.

ALQGC
Rang in aandelen #37063
Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France,... Quantum Genomics S.A., a biopharmaceutical firm established in Paris, France, in 2005, focuses on creating treatments for cardiovascular ailments. Its therapeutic approach utilizes the brain aminopeptidase A inhibition (BAPAI) platform, primarily addressing high blood pressure (hypertension) and heart failure. The company's key asset, firibastat, is currently undergoing a crucial Phase III study as a standalone therapy for hypertension and is also in clinical trials for heart failure. Additionally, Quantum Genomics is progressing QGC011 for hypertension in combination therapy, and further developing QGC006 and QGC606 to target both hypertension and heart failure.
Aandeelprijs
$0.07600875
Laatst gesynchroniseerd: 2024-11-20
Marktkapitalisatie
$2.06M
Verandering (1 dag)
-0.51%
Verandering (1 jaar)
0.00%
Land
FR
Handel Quantum Genomics S.A. (ALQGC)

Categorie

Healthcare
P/B-ratio voor Quantum Genomics S.A. (ALQGC)
P/B-ratio op August 2026 TTM: -2.05
Volgens de meest recente financiële rapporten en aandelenkoers van Quantum Genomics S.A. is de huidige P/B-ratio (TTM) -2.05. Eind 2023 had het bedrijf een P/B-ratio van 8.46.
P/B-ratiohistoriek voor Quantum Genomics S.A. van 2009 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
2026 (TTM) -2.05 -0.18%
2024 -2.05 -124.18%
2023 8.46 649.27%
2022 1.13 -90.55%
2021 11.95 194.68%
2020 4.06 -37.21%
2019 6.46 -8.65%
2018 7.07 87.24%
2017 3.78 -35.35%
2016 5.84 -20.06%
2015 7.31 -103.58%
2014 -204.14 1,261.27%
2013 -15.00 -41.14%
2012 -25.48 74.82%
2011 -14.57 70.19%
2010 -8.56 -101.36%
2009 630.17 0.00%
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -409.91%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -404.99%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -269.14%
BE